Core Insights - Novo Nordisk announced top-line results from the phase 3 evoke and evoke+ trials for oral semaglutide in early-stage symptomatic Alzheimer's disease, involving 3,808 adults [1][2] - The trials did not show superiority of semaglutide over placebo in slowing Alzheimer's disease progression, despite improvements in biomarkers [2][4] - The decision to explore semaglutide for Alzheimer's was based on real-world evidence and previous studies, although the likelihood of success was considered low [4] Study Details - The evoke and evoke+ trials were randomized, double-blind, and placebo-controlled, focusing on patients aged 55-85 with mild cognitive impairment or mild dementia due to Alzheimer's [3][7] - Semaglutide was administered at a dose of 14 mg once daily, with a total of 1,855 and 1,953 participants randomized in the two trials respectively [7] - The primary measure of efficacy was the change in Clinical Dementia Rating – Sum of Boxes (CDR-SB) score from baseline to week 104 [6][7] Safety and Tolerability - Semaglutide demonstrated a safe and well-tolerated profile consistent with previous trials, with over 37 million patient-years of exposure across various populations [3][4] - The one-year extension period of the trials will be discontinued due to the lack of efficacy observed [4] Future Presentations - Topline results will be presented at the Clinical Trials in Alzheimer's Disease (CTAD) conference on December 3, 2025, with full results to follow at the 2026 Alzheimer's and Parkinson's Diseases Conferences in March 2026 [4]

Core Viewpoint - Comstock Inc. has received eligibility notifications for key environmental permits to establish an industrial-scale solar panel processing facility in Silver Springs, Nevada, which is crucial for the company's plans to recycle end-of-life solar panels and promote sustainable practices in the industry [1][2][3]. Regulatory Approvals - The company has obtained an Air Quality Permit and a Written Determination Permit from the Nevada Division of Environmental Protection, which are essential for the operation of a facility designed to process over 3 million solar panels annually, equating to approximately 100,000 tons of waste materials [2][3]. Facility Operations - The facility will utilize advanced technologies for the efficient processing and recycling of metal concentrates from photovoltaics, with equipment already ordered and expected to be delivered by the end of the year, allowing for installation and testing in early 2026 [2][3]. Market Position - Comstock Metals is positioned as a leader in the solar panel recycling market, particularly in the southwestern U.S., where many older solar panels are being decommissioned, thus increasing the demand for responsible recycling solutions [3][4]. Environmental Impact - The company emphasizes the importance of preventing heavy metal contamination from decommissioned solar panels, aiming to keep these materials out of landfills and avoid offshoring waste management issues [3][4]. Future Expansion - Comstock is strategically assessing additional processing and storage sites to capitalize on the growing demand for end-of-life solar panel recycling, reinforcing its market leadership and setting industry standards [4].

Core Insights - Linyi Trade City from Shandong province hosted a successful quality product expo in Ghana, leading to agreements worth 16.8 million yuan ($2.36 million) with five local enterprises [1] - The expo showcased a variety of building materials and products that cater to the needs of the Ghanaian market, attracting buyers from neighboring countries due to their high quality and affordability [2] - The event highlighted the potential for Linyi's products to fill gaps in the local market, particularly in the chemical products sector, which is currently inefficient in Ghana [3] Market Potential - The Linyi merchant delegation explored Accra and Tema, identifying opportunities for establishing overseas warehouses and integrating supply chains, indicating significant investment potential [4] - The delegation's visit to the Jinyi Industrial Park reinforced confidence in Linyi's expansion into West Africa, with local officials expressing eagerness for investment and collaboration [5] - Accra's government is prepared to assist Linyi enterprises in expanding their market presence, emphasizing a strong partnership [6]

Core Viewpoint - Scilex Holding Company has entered into a definitive agreement to exercise existing warrants, which is expected to generate approximately $20.3 million in gross proceeds for the company [1][4]. Group 1: Existing Warrants - The company will exercise a total of 428,572 shares from April 2024 Warrants at an exercise price of $38.50 per share and 475,824 shares from December 2024 Warrants at an exercise price of $22.72 per share [1]. - The aggregate gross proceeds from the exercise of these existing warrants are anticipated to be around $20.3 million before deducting fees and expenses [1]. Group 2: New Warrant Issuance - In exchange for the immediate cash exercise of the existing warrants, the company will issue a new unregistered warrant to purchase up to 1,356,594 shares of common stock at an exercise price of $29.00 per share [3]. - The new warrant will be exercisable immediately upon issuance and will have a term of five years [3]. Group 3: Use of Proceeds - The net proceeds from the offering are expected to be utilized for working capital and general corporate purposes [4]. Group 4: Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for treating acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [7][8]. - The company's commercial products include ZTlido, ELYXYB, and Gloperba, which target significant unmet medical needs [8][9].

Core Insights - Rakovina Therapeutics is advancing its AI-derived PARP-1 inhibitor program, showcasing progress at the 2025 Society for Neuro-Oncology Annual Meeting [1][5] - The company is utilizing AI methods to discover and characterize novel PARP1-selective small-molecule drug candidates that penetrate the central nervous system (CNS) [2][4] Research and Development - A scientific poster titled "Discovery and development of novel CNS-penetrating PARP1-selective inhibitors" was presented, highlighting collaboration with the Vancouver Prostate Centre and the University of British Columbia [2] - The research employs Deep Docking™ and generative-AI computational approaches to screen large chemical libraries for compounds with selective inhibition of PARP1 and favorable drug-like properties [3][4] Results and Data - Hundreds of prioritized compounds have been synthesized and evaluated, with a subset showing PARP1-selective activity and promising in vitro metabolic stability and pharmacokinetic profiles [4] - The presentation included comparisons of ADME and pharmacokinetic data from synthesized compounds against existing PARP inhibitors and next-generation benchmarks [4] Company Overview - Rakovina Therapeutics focuses on innovative cancer treatments, leveraging AI technologies like Deep-Docking™ and Enki™ to enhance drug candidate optimization [6] - The company aims to advance its pipeline of DNA-damage response inhibitors into human clinical trials in collaboration with pharmaceutical partners [7]

VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Coppernico Metals Inc. (TSX: COPR, OTCQB: CPPMF, FSE: 9I3) (“Coppernico” or the “Company”), through its wholly owned private Peruvian subsidiary, Sombrero Minerales SAC, is pleased to announce that, having completed all required environmental studies, it has formally submitted an Environmental Impact Assessment – Semi-detailed ("EIA-Sd") drill permit application (the "Application") for its Sombrero Project in Peru. The permit, once granted, will ...

Core Insights - Enerflex Ltd. has appointed Ms. Céline Gerson to its Board of Directors, effective immediately [1] - Ms. Gerson brings 25 years of experience from Fortune 500 companies, enhancing the Board's skillset as Enerflex pursues its strategic goals [2] - Ms. Gerson expressed her enthusiasm for joining Enerflex at a pivotal time, emphasizing the company's commitment to sustainable shareholder value [3] About Céline Gerson - Ms. Gerson has a strong background in international business, strategy development, and commercial positioning, currently serving as President and Group Director for Fugro Americas [3][4] - She holds a B.B.A in International Finance and Marketing and a J.D., along with an Executive Leadership Development program from Harvard Business School [4] About Enerflex - Enerflex is a global provider of energy infrastructure and transition solutions, focusing on natural gas and sustainability [5] - The company employs over 4,400 professionals dedicated to transforming energy for a sustainable future [5] - Enerflex's shares are traded on the Toronto Stock Exchange and the New York Stock Exchange under the symbols "EFX" and "EFXT," respectively [6]

Core Points - Mike Lindell Media Corp. has recruited Heather Mullins as the Chief Pentagon Correspondent, enhancing its news division [1][3] - Mullins has a strong military background and extensive experience in election integrity reporting, which aligns with the company's focus [2][3] - The company aims to provide unbiased coverage from the Pentagon, alongside its existing reporting from the White House and Capitol Hill [3][4] Company Overview - Mike Lindell Media Corp. operates a conservative broadcast network, providing an alternative to mainstream media through its platforms, LindellTV and VOCL [4] - The company has grown to serve over 7 million monthly viewers and has recently gained press access to White House events [4] - LindellTV was rebranded from frankspeech.com in February 2025, and VOCL was rebranded from FrankSocial in September 2024 [4] Personnel and Expertise - Heather Mullins has a background in investigative journalism, particularly in election integrity, and has previously contributed to various media outlets [3] - Mullins expressed her honor in joining LindellTV, emphasizing her commitment to serving the military and the country through journalism [2][3] - Mike Lindell, the CEO, highlighted Mullins as a tremendous asset to the company, expecting her to deliver significant stories from the Pentagon [3]

DELTA, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- RecycLiCo Battery Materials Inc. (“RecycLiCo” or the “Company”) (TSX.V: AMY | OTCQB: AMYZF |FSE: ID4), a critical minerals refining and lithium-ion battery upcycling company, today announced that Andris Kikauka, who is retiring from the Company’s Board of Directors, will continue as a consultant to support the ongoing management and maintenance of RecycLiCo’s legacy mining assets. In this consulting role, Mr. Kikauka will have day-to-day advisory re ...

Core Viewpoint - Alvotech has received approval from the European Commission for AVT03 as a biosimilar to Prolia and Xgeva, which is expected to enhance access to treatments for osteoporosis and cancer-related skeletal issues in Europe [1][4][5]. Company Summary - Alvotech is a global biotech company focused on developing and manufacturing biosimilar medicines, aiming to be a leader in the biosimilar space by providing high-quality, cost-effective products [11]. - The approval of AVT03 reflects Alvotech's strong end-to-end platform and its commitment to delivering affordable medicines to patients [4][5]. - Alvotech has established strategic partnerships for the commercialization of AVT03 in Europe, collaborating with STADA and Dr. Reddy's, each holding semi-exclusive rights in various regions [7][12]. Product Summary - AVT03 is approved in two forms: as a 60 mg/mL single-use pre-filled syringe for osteoporosis treatment and as a 70 mg/mL single-use vial for preventing skeletal-related events in cancer patients [3][9]. - The European denosumab market is valued at approximately US$1.2 billion, indicating a significant opportunity for AVT03 to capture market share [2]. - The approval was based on comprehensive evidence, including pharmacokinetic and pharmacodynamic data, and clinical studies demonstrating equivalent efficacy and safety compared to the reference products [8]. Market Context - Osteoporosis-related disabilities in Europe surpass those caused by common cancers, highlighting the importance of effective treatments [6]. - The economic burden of fragility fractures in Europe was estimated at €57 billion in 2019, underscoring the need for cost-effective treatment options like biosimilars [6][7].